Krankenhaus Jerusalem

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.5K citations · Full text

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Sibylle Loibl, Karsten E. Weber, Kirsten M. Timms et al. · Annals of Oncology · 2018 · 282 citations · Full text

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)

Andreas du Bois, Philipp Harter, Christina Fotopoulou et al. · International Journal of Gynecological Cancer · 2019 · 167 citations

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Bradley J. Monk, Rachel N. Grisham, Susana Banerjee et al. · Journal of Clinical Oncology · 2020 · 144 citations · Full text

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Michael Friedländer, Val Gebski, Emma Gibbs et al. · The Lancet Oncology · 2018 · 135 citations · Full text

Olaparib Maintenance, Health-related Quality, Medicine +9